,

Wenyi Jin1,2,3, Yubiao Zhang2, Zhijie Zhao4

  • 1Department of Orthopedics, Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, The Third Affiliated Hospital of Shanghai University, Wenzhou People's Hospital, Wenzhou, China, 325041.

Theranostics
|July 1, 2024
PubMed
概括

这项研究揭示了代谢重编程如何驱动神经母细胞瘤 (NB) 的进展. 一个新的预后签名 (MPS) 预测NB风险,并指导 AZD7762 和 etoposide 等向治疗,以获得更好的患者结果.